The pharmaceutical industry is witnessing a significant shift as European outsourcing facilities increasingly attract attention, leaving US counterparts behind. This trend is largely driven by favorable national tax systems in Europe, which are incentivizing companies to relocate their manufacturing operations. As a result, the gap in new drug manufacturing capabilities between Europe and the US is widening.
This shift not only highlights the changing dynamics in global pharmaceutical manufacturing but also raises concerns about the long-term implications for US competitiveness in the sector. As companies prioritize cost-effective solutions and regulatory efficiencies, the US may face challenges in retaining its status as a leading hub for pharmaceutical innovation. The implications for regulatory, quality assurance, and sourcing professionals are profound, as they must adapt to a landscape where Europe is increasingly seen as the go-to destination for new drug manufacturing.
Open the full market picture for your next decision →
